

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



00004445-3
(ref only)

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 265/36, 279/16, A61K 31/535, 31/54		A1	(11) International Publication Number: WO 99/50257 (43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/US98/26708 (22) International Filing Date: 15 December 1998 (15.12.98) (30) Priority Data: 60/080,142 31 March 1998 (31.03.98) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BERRYMAN, Kent, Alan [US/US]; P.O. Box 2494, Silverthorne, CO 80498 (US). DOWNING, Dennis, Michael [US/US]; 3737 Burbank, Ann Arbor, MI 48105 (US). DUDLEY, Danette, Andrea [US/US]; 290 Village Green Boulevard #201, Ann Arbor, MI 48105 (US). EDMUNDS, Jeremy, John [GB/US]; 3957 Beech Drive, Ypsilanti, MI 48197 (US). NARASIMHAN, Lakshmi, Sourirajan [IN/US]; 45680 Larchmont Drive, Canton, MI 48197 (US). RAPUNDALO, Stephen, Taras [CA/US]; 3106 Blucett Road, Ann Arbor, MI 48105 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.			(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS			
(57) Abstract This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.			